Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
Confo Therapeutics SA
HK inno.N Corp
MorphoSys AG
Novopyxis Inc
Shandong Danhong Pharmaceutical Co Ltd
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
Product Description
Mechanism Of Action
History of Events
C-106 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CFTX-1554 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NP-6A - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
thalidomide - Drug Profile
Product Description
Mechanism Of Action
History of Events
VP-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VP-03 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WXSH-0024 - Drug Profile
Product Description
Mechanism Of Action
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2022: Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody drug discovery and development technology in rare diseases
Jun 17, 2022: Vicore Pharma starts Phase I trial of angiotensin II type 2 receptor agonist
Jun 03, 2022: Vicore amends primary endpoint to accelerate the Phase 3 trial in COVID-19 patients
Mar 18, 2022: Vicore initiates human forearm blood flow study with C21
Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain
Mar 10, 2022: Confo Therapeutics doses first subjects in phase 1 clinical trial of CFTX-1554 for the treatment of neuropathic pain
Mar 09, 2022: Vicore strengthens rare lung disease pipeline with PAH indication
Mar 04, 2022: Vicore to host R&D-Day
Mar 04, 2022: Vicore to host R&D Day
Feb 10, 2022: Vicore’s AIR study interim alysis suggests that C21 improves lung function in IPF patients
Dec 15, 2021: Confo Therapeutics expands patent estate for ConfoBody-based GPCR screening platform
Nov 02, 2021: Vicore’s C21 reduces long-term lung injury after COVID-19 in the ATTRACT Phase 2 extension study
Oct 25, 2021: Vicore Pharma Holding: Lancet’s EClinicalMedicine publishes phase 2 data on C21 in COVID-19
Sep 22, 2021: Vicore to host Key Opinion Leader webir on C21 for the treatment of idiopathic pulmory fibrosis (IPF)
Sep 22, 2021: Vicore obtains SARS corovirus patent for C21 in the USA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Confo Therapeutics SA, 2022
Pipeline by HK inno.N Corp, 2022
Pipeline by MorphoSys AG, 2022
Pipeline by Novopyxis Inc, 2022
Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
Pipeline by Vicore Pharma AB, 2022
Dormant Projects, 2022
Discontinued Products, 2022